insulin degludec and insulin aspart (Ryzodeg 70/30)
insulin degludec and insulin aspart is an FDA-licensed reference biologic from Novo Nordisk Inc.. Reference exclusivity, biosimilar lineage, and published patents from official FDA Purple Book records.
0
Biosimilars
0
Interchangeables
0
Listed patents
2015
Reference approved
Reference product
Ryzodeg 70/30 insulin degludec and insulin aspart
Novo Nordisk Inc.
- Approved
- Sep 25, 2015
- Marketing
- Disc
- Center
- CDER
- Patents
- None listed
Exclusivity & patent cliffs
Approval, exclusivity, and published-patent expiration dates for insulin degludec and insulin aspart, in chronological order.
Reference approval
Approval date of the reference insulin degludec and insulin aspart product.
10 yr 10 mo ago
Frequently asked questions
Are there biosimilars approved for insulin degludec and insulin aspart (Ryzodeg 70/30)?
No 351(k) biosimilars or interchangeable biosimilars referencing insulin degludec and insulin aspart are listed in the FDA Purple Book yet.
Explore the full FDA Purple Book
Search every FDA-licensed biologic, biosimilar, and interchangeable with exclusivity timelines and patent records.